$NUGN
Livento Group Inc Stock $nugn

$nugn Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224032736 Filed on August 16, 2024

Income Statement

Concept	2024 Q2	2023 Q4	2023 Q2
Revenue	$558.7K		$431.2K
YoY Change	29.58%		91.65%
Cost Of Revenue	$626.9K		$518.2K
YoY Change	20.99%		13.22%
Gross Profit	-$68.21K		-$86.99K
YoY Change	-21.59%		-62.62%
Gross Profit Margin	-12.21%		-20.17%
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses	$34.31K		$2.376M
YoY Change	-98.56%		3003.34%
Operating Profit	-$102.5K		-$2.463M
YoY Change	-95.84%		696.41%
Interest Expense			$0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net	$365.3K		$0.00
YoY Change
Pretax Income
YoY Change
Income Tax	$0.00		$1.240K
% Of Pretax Income
Net Earnings	$262.8K		-$2.463M
YoY Change	-110.67%		696.41%
Net Earnings / Revenue	47.04%		-571.18%
Basic Earnings Per Share	$0.00		$0.00
Diluted Earnings Per Share	$0.00		$0.00
COMMON SHARES
Basic Shares Outstanding		812.8M shares	294.9M shares
Diluted Shares Outstanding			294.9M shares

Balance Sheet

Concept	2024 Q2	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents	$7.970K	$30.63K	$43.43K
Short-Term Investments
Other Short-Term Assets	$440.1K	$355.0K	$280.9K
YoY Change	56.66%	192.28%
Inventory	$0.00	$0.00	$0.00
Prepaid Expenses
Receivables	$2.778M	$682.1K	$206.9K
Other Receivables
Total Short-Term Assets	$3.226M	$1.068M	$531.3K
YoY Change	507.18%	68.01%
LONG-TERM ASSETS
Property, Plant & Equipment	$26.11K	$26.82K	$53.28K
YoY Change	-51.0%
Goodwill	$0.00	$0.00	$0.00
YoY Change
Intangibles	$49.49M	$45.14M	$49.06M
YoY Change	0.88%	254.67%
Long-Term Investments
YoY Change
Other Assets	$0.00	$0.00
YoY Change
Total Long-Term Assets	$44.84M	$45.79M	$46.14M
YoY Change	-2.83%	101.91%
TOTAL ASSETS
Total Short-Term Assets	$3.226M	$1.068M	$531.3K
Total Long-Term Assets	$44.84M	$45.79M	$46.14M
Total Assets	$48.06M	$46.86M	$46.67M
YoY Change	2.97%	100.98%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$355.2K	$323.9K	$359.8K
YoY Change	-1.28%	132.16%
Accrued Expenses	$250.3K	$85.67K	$31.02K
YoY Change	706.93%	36.96%
Deferred Revenue
YoY Change
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$605.5K	$409.6K	$390.8K
YoY Change	54.94%	-87.39%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$605.5K	$409.6K	$390.8K
Total Long-Term Liabilities
Total Liabilities	$4.104M	$3.838M	$3.683M
YoY Change	11.42%	18.16%
SHAREHOLDERS EQUITY
Retained Earnings	-$18.27M	-$18.92M	-$17.42M
YoY Change	4.85%	51.94%
Common Stock	$83.12K	$22.70K	$29.49K
YoY Change	181.87%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity		$43.02M
YoY Change
Total Liabilities & Shareholders Equity	$48.06M	$46.86M	$46.67M
YoY Change	2.97%	100.98%

Cashflow Statement

Concept	2024 Q2	2023 Q2
OPERATING ACTIVITIES
Net Income	$262.8K	-$2.463M
YoY Change	-110.67%	696.41%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities	-$40.06K	$277.5K
YoY Change	-114.44%	73.1%
INVESTING ACTIVITIES
Capital Expenditures	$0.00	$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities	$4.956K	-$760.0K
YoY Change	-100.65%	406.67%
FINANCING ACTIVITIES
Cash Dividend Paid	$0.00	$0.00
YoY Change
Common Stock Issuance & Retirement, Net	$28.02K	$229.5K
YoY Change	-87.79%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$28.02K	$429.5K
YoY Change	-93.48%
NET CHANGE
Cash From Operating Activities	-$40.06K	$277.5K
Cash From Investing Activities	$4.956K	-$760.0K
Cash From Financing Activities	$28.02K	$429.5K
Net Change In Cash	-$7.085K	-$53.06K
YoY Change	-86.65%	-615.16%
FREE CASH FLOW
Cash From Operating Activities	-$40.06K	$277.5K
Capital Expenditures	$0.00	$0.00
Free Cash Flow	-$40.06K	$277.5K
YoY Change	-114.44%	73.1%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic		shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding		shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic		shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding		shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic		shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding		shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic		shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding		shares
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	831244362	shares
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	7970	usd
CY2024Q2	NUGN	Total Checking Savings TotalCheckingSavings	7970	usd
CY2024Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2777595	usd
CY2024Q2	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	440082	usd
CY2024Q2	us-gaap	Inventory Net InventoryNet	0	usd
CY2024Q2	us-gaap	Other Assets Current OtherAssetsCurrent	440082	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	3225647	usd
CY2024Q2	us-gaap	Long Term Investments LongTermInvestments	687568	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	26110	usd
CY2024Q2	us-gaap	Goodwill Goodwill	0	usd
CY2024Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	49485595	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	0	usd
CY2024Q2	NUGN	Deferred Long Term Asset Charges DeferredLongTermAssetCharges	0	usd
CY2024Q2	NUGN	Accumulated Amortization Depreciation AccumulatedAmortizationDepreciation	-5363865	usd
CY2024Q2	us-gaap	Assets Noncurrent AssetsNoncurrent	44835408	usd
CY2024Q2	us-gaap	Assets Assets	48061055	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	355157	usd
CY2024Q2	NUGN	Credit Cards CreditCards	0	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	250294	usd
CY2024Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	usd
CY2024Q2	us-gaap	Notes And Loans Payable Current NotesAndLoansPayableCurrent	0	usd
CY2024Q2	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	0	usd
CY2024Q2	us-gaap	Notes Payable Current NotesPayableCurrent	0	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	250294	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	605451	usd
CY2024Q2	NUGN	Co Investments CoInvestments	3472020	usd
CY2024Q2	NUGN	Long Term Business Loans LongTermBusinessLoans	26383	usd
CY2024Q2	us-gaap	Liabilities Other Than Longterm Debt Noncurrent LiabilitiesOtherThanLongtermDebtNoncurrent	3498403	usd
CY2024Q2	us-gaap	Liabilities Liabilities	4103854	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	62111943	usd
CY2024Q2	NUGN	Capital Stock CapitalStock	0	usd
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	83124	usd
CY2024Q2	NUGN	Common Stock Value Issued After Annual General Meeting CommonStockValueIssuedAfterAnnualGeneralMeeting	0	usd
CY2024Q2	NUGN	Dividends Paid DividendsPaid	0	usd
CY2024Q2	NUGN	Opening Balance Equity OpeningBalanceEquity	0	usd
CY2024Q2	us-gaap	Members Capital MembersCapital	0	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	19931	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-18268818	usd
CY2024Q2	us-gaap	Minority Interest MinorityInterest	11020	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43957200	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	48061055	usd
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	558707	usd
CY2024Q2	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	626915	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	-68208	usd
CY2024Q2	us-gaap	Advertising Expense AdvertisingExpense	408	usd
CY2024Q2	NUGN	Computer And Internet Expenses ComputerAndInternetExpenses	0	usd
CY2024Q2	NUGN	Bank Service Charges BankServiceCharges	1347	usd
CY2024Q2	us-gaap	Insurance Commissions InsuranceCommissions	0	usd
CY2024Q2	us-gaap	Other Cost And Expense Operating OtherCostAndExpenseOperating	12001	usd
CY2024Q2	us-gaap	Professional And Contract Services Expense ProfessionalAndContractServicesExpense	1688	usd
CY2024Q2	us-gaap	Other General Expense OtherGeneralExpense	570	usd
CY2024Q2	us-gaap	Interest Expense Operating InterestExpenseOperating	7694	usd
CY2024Q2	us-gaap	General Insurance Expense GeneralInsuranceExpense	0	usd
CY2024Q2	us-gaap	Legal Fees LegalFees	3750	usd
CY2024Q2	us-gaap	Professional Fees ProfessionalFees	600	usd
CY2024Q2	us-gaap	Administrative Fees Expense AdministrativeFeesExpense	2058	usd
CY2024Q2	us-gaap	Other Labor Related Expenses OtherLaborRelatedExpenses	0	usd
CY2024Q2	NUGN	Rental Expense RentalExpense	738	usd
CY2024Q2	us-gaap	Travel And Entertainment Expense TravelAndEntertainmentExpense	361	usd
CY2024Q2	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	9	usd
CY2024Q2	us-gaap	Employee Benefits And Share Based Compensation EmployeeBenefitsAndShareBasedCompensation	3100	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	0	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	34306	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-102515	usd
CY2024Q2	us-gaap	Other Income OtherIncome	365307	usd
CY2024Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	usd
CY2023Q2	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	0	usd
	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	11	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	365307	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	262792	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0
CY2024Q2	us-gaap	Profit Loss ProfitLoss	262792	usd
CY2024Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax OtherComprehensiveIncomeLossNetOfTax	992	usd
CY2024Q2	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-31915	usd
CY2024Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	231870	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	20067160	usd
	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	6197	usd
	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	45949	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	27832402	usd
	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	-4972359	usd
	NUGN	Stock Issued During Period Value Change In Non Controlling Interest StockIssuedDuringPeriodValueChangeInNonControllingInterest	11020	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42990369	usd
CY2023Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43021998	usd
	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	6050	usd
	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	1844	usd
	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	172169	usd
	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	755138	usd
	NUGN	Stock Issued During Period Value Change In Non Controlling Interest StockIssuedDuringPeriodValueChangeInNonControllingInterest	0	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43957200	usd
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	19827661	usd
CY2023Q2	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	3291	usd
CY2023Q2	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	43849	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	25579804	usd
CY2023Q2	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	-2475254	usd
CY2023Q2	NUGN	Stock Issued During Period Value Change In Non Controlling Interest StockIssuedDuringPeriodValueChangeInNonControllingInterest	11020	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	42990369	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43694247	usd
CY2024Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43694247	usd
CY2024Q2	NUGN	Stock Issued During Period Value Change In Preferred Shares StockIssuedDuringPeriodValueChangeInPreferredShares	4550	usd
CY2024Q2	NUGN	Stock Issued During Period Value Change In Ordinary Shares StockIssuedDuringPeriodValueChangeInOrdinaryShares	4	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	26567	usd
CY2024Q2	NUGN	Stock Issued During Period Value Change In Accumulated Deficit StockIssuedDuringPeriodValueChangeInAccumulatedDeficit	231832	usd
CY2024Q2	NUGN	Stock Issued During Period Value Change In Non Controlling Interest StockIssuedDuringPeriodValueChangeInNonControllingInterest	0	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43957200	usd
CY2024Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	43957200	usd
CY2024Q2	us-gaap	Profit Loss ProfitLoss	262792	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-2462842	usd
	us-gaap	Profit Loss ProfitLoss	818364	usd
	us-gaap	Profit Loss ProfitLoss	-4959946	usd
CY2024Q2	us-gaap	Adjustment For Amortization AdjustmentForAmortization	-30028	usd
CY2024Q2	us-gaap	Share Based Compensation ShareBasedCompensation	525934	usd
CY2024Q2	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-3100	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	874331	usd
CY2024Q2	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-25268	usd
CY2024Q2	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	31535	usd
CY2024Q2	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	129274	usd
CY2024Q2	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	-302854	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40061	usd
CY2024Q2	us-gaap	Payments For Proceeds From Longterm Investments PaymentsForProceedsFromLongtermInvestments	-0	usd
CY2024Q2	us-gaap	Payments For Proceeds From Productive Assets PaymentsForProceedsFromProductiveAssets	-4956	usd
CY2024Q2	us-gaap	Proceeds From Sale Of Other Investments ProceedsFromSaleOfOtherInvestments	0	usd
CY2024Q2	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2024Q2	us-gaap	Proceeds From Other Deposits ProceedsFromOtherDeposits	0	usd
CY2024Q2	NUGN	Proceeds From Security Deposits Asset ProceedsFromSecurityDepositsAsset	0	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	4956	usd
CY2024Q2	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	28021	usd
CY2024Q2	us-gaap	Proceeds From Contributions From Affiliates ProceedsFromContributionsFromAffiliates	0	usd
CY2024Q2	us-gaap	Payments Of Dividends PaymentsOfDividends	-0	usd
CY2024Q2	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2024Q2	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	28021	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-7085	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15054	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7970	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_80E_eus-gaap--NatureOfOperations_zvrDRDkPFBWg" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>NOTE 1 - <span id="xdx_82B_zTY0i8vaSp51">NATURE OF BUSINESS AND BASIS OF PRESENTATION</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">We were incorporated in the State of Nevada on October 30, 2013, under the name “Bling Marketing, Inc.”. Until December 29, 2014, we were a wholesaler of jewelry, principally earrings, rings, and pendants (“BMI Business”). We recognized a minimal number of sales from operations before the three months ending June 30, 2014 and were accordingly classified as a shell company. During the three-month ended June 30, 2014, we began working with several distributors to sell our jewelry products to retail outlets and, as a result, recognized sales revenue of $<span id="xdx_90F_eus-gaap--Revenues_c20140401__20140630__dei--LegalEntityAxis__custom--BlingMarketingIncMember_zNlsTD3jixva" title="Sales revenue">22,025</span> during the said period. On September 11, 2014, we filed a Current Report on Form 8-K indicating that we were no longer a shell company as defined by Rule12b-2 of the Exchange Act in light of our operations through the quarter that ended June 30, 2014.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 26, 2014, we entered into an Agreement and Plan of Merger (“Nugene Merger Agreement”) with NuGene Inc., a California corporation (“NuGene”). On December 29, 2014 (the “Closing Date”), we filed a certificate of merger in the State of California whereby our subsidiary, NG Acquisition Inc. (“Acquisition Sub”), merged with NuGene. As a result, NuGene, the surviving entity, became our wholly owned subsidiary. The transaction under the Nugene Merger Agreement was deemed to be a reverse merger, whereby the Company (the legal acquirer) is considered the accounting acquiree and NuGene is considered the accounting acquirer, and NuGene (the legal acquiree) is considered the accounting acquirer. The assets, liabilities, and operations of the acquired entity, NuGene, were brought forward at their book value, and no goodwill was recognized.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In connection with the NuGene Merger Agreement, we entered into a Business Transfer and Indemnity Agreement dated December 29, 2014 (the “Indemnity Agreement”) with our former Chief Executive Officer and Director, Dena Kurland providing for:</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The transfer of our jewelry business operations existing on the date of the Indemnity Agreement (the “BMI Business”);</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The assumption by Ms. Kurland of all liabilities of our Company and the indemnification by Ms. Kurland holding our Company harmless for any and all liabilities arising at or before the date of the Indemnity Agreement;</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The payment by NuGene to Ms. Kurland of $<span id="xdx_907_eus-gaap--PaymentsToAcquireBusinessesGross_c20141229__20141229__dei--LegalEntityAxis__custom--NuGeneIncMember__srt--TitleOfIndividualAxis__custom--MsKurlandMember_z6aLSUBnyb0b" title="Cash payment for acquisition">350,000</span> in cash; and</span></td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">●</span></td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The surrender by Ms. Kurland of <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesShareBasedCompensationForfeited_c20141229__20141229__srt--TitleOfIndividualAxis__custom--MsKurlandMember__dei--LegalEntityAxis__custom--NuGeneIncMember_z6s0Vxw3JYZ3" title="Shares surrendered">15,000,000</span> shares (before giving effect to the Stock Split discussed below) (the “Indemnity Shares”) of our Company’s common stock representing <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_pid_dp_uPure_c20141229__20141229__dei--LegalEntityAxis__custom--NuGeneIncMember__srt--TitleOfIndividualAxis__custom--MsKurlandMember_zyp9RtL8mhSj" title="Common stock, percentage">95</span>% of the then outstanding common stock (all of which shares have been deemed cancelled by the Company).</span></td></tr> </table> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant to the terms of the Nugene Merger Agreement, <span id="xdx_90A_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zRsVeokryAo5" title="Stock issued during period shares new issues">26,052,760</span> shares of Company common stock and <span id="xdx_900_eus-gaap--StockIssuedDuringPeriodSharesAcquisitions_pid_c20141226__20141226__dei--LegalEntityAxis__custom--NuGeneIncMember__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember_zBMEWSl2zJX9" title="Stock issued during acquisition">1,917,720</span> Company a newly designated Series A Preferred Stock were issued to the former NuGene shareholders. The Series A Preferred Stock was: (i) <span id="xdx_909_eus-gaap--ConvertiblePreferredStockTermsOfConversion_pid_c20141226__20141226__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--NuGeneIncMember_zPQScbBDmMfj" title="Preferred stock conversion terms">initially convertible into common stock at a ratio of one to one</span>, (ii) <span id="xdx_90C_eus-gaap--PreferredStockParticipationRights_pid_c20141226__20141226__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--NuGeneIncMember_zRKbsWppo3d5" title="Preferred stock rights description">as long as there were a minimum of 900,000 shares of Series A Preferred Stock outstanding, the holders of the Series A Preferred Stock had the right to elect a majority of the board of directors</span> and (iii) <span id="xdx_906_eus-gaap--PreferredStockVotingRights_pid_c20141226__20141226__us-gaap--TypeOfArrangementAxis__custom--NugeneMergerAgreementMember__us-gaap--StatementClassOfStockAxis__us-gaap--SeriesAPreferredStockMember__dei--LegalEntityAxis__custom--NuGeneIncMember_zetR72Kery3j" title="Preferred stock voting rights">the holders of the Series A Preferred Stock, generally voting as a class with the holders of common stock, had for each share of Series A Preferred Stock three times the number of votes permitted to each share of common stock</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 26, 2014, <span id="xdx_909_eus-gaap--StockholdersEquityReverseStockSplit_c20141226__20141226__srt--TitleOfIndividualAxis__srt--DirectorMember_zcERWAyO1Unk" title="Reverse stock split description">our board of directors approved a 15.04 to one stock split (“Stock Split”) in the form of a stock dividend to holders of our common stock as of that date. To affect that board action, each recipient of the stock dividend would receive 14.04 additional shares of common stock for every share of common stock held</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On December 29, 2014, we completed the sale of <span id="xdx_90D_eus-gaap--SaleOfStockNumberOfSharesIssuedInTransaction_pid_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zsrNLKhWdH8e" title="Sale of stock shares">2,000,000</span> shares of our common stock to 18 purchasers (“Stock Placement”) for proceeds totaling $<span id="xdx_90C_eus-gaap--SaleOfStockConsiderationReceivedOnTransaction_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember_zhq7lJeLI1Qd" title="Proceeds from sale of stock">2,000,000</span>, including (a) $<span id="xdx_907_eus-gaap--ProceedsFromIssuanceOfCommonStock_c20141229__20141229__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember_z0Xf8R6x0Xue" title="Cash proceeds from sale of stock">1,625,000</span> of cash and (b) automatic conversion of promissory notes in the principal amount of $<span id="xdx_90D_eus-gaap--DebtConversionOriginalDebtAmount1_c20141229__20141229__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember__us-gaap--SubsidiarySaleOfStockAxis__custom--StockPlacementMember_zm1kHPHV6ktd" title="Note principal amount converted">375,000</span>.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NuGene was incorporated in California in December 2006 and formed and funded by our founders, Ali Kharazmi and Mohammed Kharazmi, M.D. The initial focus of NuGene was to develop and market customized skin care products. As part of that focus, NuGene sought to leverage the working relationships developed by our founders with the plastic surgery community. NuGene directed significant time and resources on developing anti-aging and scar treatment/reduction products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2007 Nugene continued to focus on “age-defying” products utilizing peptide complexes (see further description below) and nano-encapsulation for absorption into the skin (see additional description below). We introduced a limited product line under the NuGene name and co-branded the products with an affiliated entity, Genetic Institute of Anti-Aging, Inc. (“GIAA”), which the Kharazmi owned. We utilized the services of a Korean-based contract manufacturer to supply our products. This product line (the “GIAA Line”) was based on peptides and did not utilize stem cells. We had very modest sales in 2007, with our sole customer GIAA, a related party.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2008 we stopped production of the GIAA Line, and sales were limited to selling the remaining inventory through medical offices and GIAA. With the GIAA Line discontinued, we spent the remainder of 2008 considering different formulations and methodologies for improved anti-aging products.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2009 and 2010, we had limited activity and minimal sales. Our sales were mainly overseas and limited to the remaining inventory of the GIAA Line. We continued to explore how we might advance our formulations and methodologies. We expended funds on research and development, carried out mainly by scientists engaged by the Company.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2011 our founders decided to use adult adipose human stem cells (undifferentiated cells found throughout the body that multiply by cell division to replenish dying cells and regenerate tissues) as the foundation of the formulation for its products. In 2011 the Company developed a proprietary process to extract human adult stem cells from fat cells that the Company then used in its customized NuGene line explicitly made for those client(s). Throughout 2011 we continued to provide autologous, or mature, fat-derived stem cells for use in clinical procedures utilizing this technology. Through this process, the Company refined its ability to culture adult human stem cells to render human-conditioned stem cell media at a proprietary concentration, a primary ingredient in the NuGene line of cosmeceuticals. The Company believes that this proprietary concentration, combined with our unique formulations, will provide NuGene with a significant competitive advantage.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2012 we completed our initial line of cosmeceutical products based on these adipose-derived stem cells. We branded this advanced skincare line solely under the NuGene name (the “NuGene Line”). We eliminated the unpleasant odor associated with stem cells by adding a fragrance with a very low incidence of allergic reaction. The packaging of this new product line bears no resemblance to the prior GIAA Line. We also manufactured the NuGene Line ourselves at a small laboratory facility that we leased from an affiliated entity owned by one of our founders.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Throughout 2013 we continued to expand the product offerings of the NuGene Line. The Company focused its stem cell work on surgical and orthopedic regeneration. These services were delivered to one client, which was an affiliated entity. Sales of the NuGene Line were limited as we were in an initial rollout and branding phase.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">During 2014, we focused our efforts on transitioning to a cosmeceutical skincare business for mass distribution. With this transition and expanded attention to our consumer products, we sought to develop our marketing plan and distribution channels. By the end of 2014, we had wholesalers distributing products from the NuGene Line to medical offices and medical spas throughout the United States. December 31, 2014, we had about 50 locations selling our products. In addition to the NuGene Line, we generated revenues from an affiliate, Advanced Surgical Partners (“ASP”), which is also owned by our CEO and Chairman of the Board, Messrs. Ali and Mohammed Kharazmi, respectively. Revenues generated from ASP resulted from NuGene providing Plasma Rich Platelet and Stem Cell injections for orthopedic and plastic surgery procedures to ASP. We provided these products and services to ASP as we transitioned into commercializing our cosmeceutical product lines. We expect further to minimize these product sales and services to ASP in early 2015.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our target customers primarily consisted of middle-aged men and women concerned with their aging skin and hair loss. Although our distributors were primarily west of the Mississippi River, our products were sold throughout the United States.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By 2017, our cosmeceutical skincare business had been discontinued as we could not obtain financing for operations on reasonable terms and became inactive. Our corporate charter was revoked in Nevada</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">On January 26, 2020, Emergent, LLC (“Emergent”), a Nevada LLC controlled by Milan I Hoffman, was appointed the custodian of the Company and proceeded to revive the Company’s existence and resolve its outstanding indebtedness. This was completed as to all indebtedness except for one convertible rate promissory note of $<span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20200126__us-gaap--DebtInstrumentAxis__custom--PromissoryNoteMember_zuATRllX6um5" title="Note amount">120,000</span>. See Litigation. In March 2022, Ms. Hoffman sold her Series A Preferred stock in the Company and certain shares of Series C Preferred Stock to Livento Group, LLC. Also in March 2022, David Stybr, our CEO and the sole owner of Livento Group, LLC, agreed to contribute Livento Group, LLC to the Company in exchange for a transfer to him of the Series A Preferred Stock which gave Mr. Stybr voting control of the Company. The Series C Preferred Stock purchased by Livento Group, LLC was cancelled. As a result of these transactions our current operations are the operations of Livento Group, LLC</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Livento Group operations started in 2017 as the internal team spearheaded the development of financial management software based on artificial intelligence for investment entities. This software currently provides several clients with data processing and analytical services in the investment management sector. Management believes that this segment of our operations will provide meaningful revenue, but we can give no assurance that this will happen. The product is best described as an automated system that can analyze large quantities of data, focusing on selected parameters and predicting short-term future behavior within a specific portfolio of selected assets. The software chooses assets with the highest potential based on a set of specifications and properties, predicting short-term future behavior within a particular portfolio.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">In 2020 the Company acquired land for a residential real estate development project, amounting to <span id="xdx_90F_eus-gaap--PaymentsToAcquireResidentialRealEstate_pn6n6_c20200101__20201231_zZ9sNa6eklg2" title="Payments to acquire residential real estate land">4</span> million USD, with a completion target of late 2022.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2020	us-gaap	Payments To Acquire Residential Real Estate PaymentsToAcquireResidentialRealEstate	4000000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_zZXpFFuGlpKd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_862_zbU2T8eJqzLc">Use of Estimates</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Conformity with GAAP requires the use of estimates and judgments that affect the reported amounts in the financial statements and accompanying notes. These estimates form the basis for judgments we make about the carrying values of our assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical information and on various other assumptions that we believe are reasonable under the circumstances. GAAP requires us to make estimates and judgments in several areas, including but not limited to, those related to revenue recognition, collectability of accounts receivable, contingent liabilities, fair value of financial instruments, fair value of acquired intangible assets and goodwill, useful lives of intangible assets and property and equipment, excess and obsolete inventory, deferred tax asset valuation and income taxes. These estimates are based on management’s knowledge about current events and expectations about actions we may undertake in the future. Actual results could differ materially from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_840_eus-gaap--ConcentrationRiskCreditRisk_zhmli8cSaxW7" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_865_zB7QXJu7o6Rf">Risks and Uncertainties</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company operates in an industry that is subject to rapid change. The Company’s operations are subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks, including the potential of business failure.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_84A_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z8eZSbOOpJS5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span style="text-decoration: underline"><span id="xdx_86E_zIFuwnlBSQYc">Reclassifications</span></span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">For comparability, certain prior period amounts have been reclassified, where appropriate, to conform to the current year’s financial statement presentation. These reclassifications have no impact on net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	558707	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	530429	usd
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	831244362	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	831244362	shares
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
	us-gaap	Operating Lease Expense OperatingLeaseExpense	4500	usd
CY2024Q2	us-gaap	Lessee Operating Lease Discount Rate LesseeOperatingLeaseDiscountRate	0.03	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	59000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	61000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	120000	usd

Files In Submission

Name	View Source	Status
0001493152-24-032736-index-headers.html	Edgar Link	pending
0001493152-24-032736-index.html	Edgar Link	pending
0001493152-24-032736.txt	Edgar Link	pending
0001493152-24-032736-xbrl.zip	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nugn-20240630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
nugn-20240630_cal.xml	Edgar Link	unprocessable
nugn-20240630_def.xml	Edgar Link	unprocessable
nugn-20240630_pre.xml	Edgar Link	unprocessable
nugn-20240630_lab.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$NUGN
Livento Group Inc Stock $nugn

2024 Q2 Form 10-Q Financial Statement

#000149315224032736 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUGN Livento Group Inc Stock $nugn

2024 Q2 Form 10-Q Financial Statement

#000149315224032736 Filed on August 16, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$NUGN
Livento Group Inc Stock $nugn